| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| KRYSKrystal Biotech, Inc. | 8.18B | 282.01 | 94.00 | 473.02% | 53.3% | 17.48% | 1.46% | 0.01 |
| BMRNBioMarin Pharmaceutical Inc. | 10.58B | 55.07 | 24.92 | 17.97% | 16.82% | 8.59% | 4.49% | 0.11 |
| SRPTSarepta Therapeutics, Inc. | 2.23B | 21.31 | 9.11 | 52.97% | -11.25% | -20.57% | 0.88 | |
| RAREUltragenyx Pharmaceutical Inc. | 2.27B | 23.50 | -3.74 | 29.01% | -91.95% | -35.88% | 0.15 | |
| DYNDyne Therapeutics, Inc. | 2.7B | 16.42 | -4.87 | -61.26% | 0.04 | |||
| TVTXTravere Therapeutics, Inc. | 2.54B | 28.40 | -6.96 | 60.55% | -20.32% | -120.36% | 6.80 | |
| BEAMBeam Therapeutics Inc. | 3.25B | 32.05 | -7.00 | -83.18% | -7.44% | -42.92% | 0.22 | |
| SLNOSoleno Therapeutics, Inc. | 2.25B | 41.95 | -9.58 | -79.5% | -15.85% | 0.22 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 1.25M | 5.42M | 154.58M | 301.03M | 380.83M | 540.1M | 701.89M | 933.01M | 1.24B | 1.9B |
| Revenue Growth % | -0.87% | 3.33% | 27.52% | 0.95% | 0.27% | 0.42% | 0.3% | 0.33% | 0.33% | 0.53% |
| Cost of Goods Sold | 146.19M | 130K | 7.35M | 34.19M | 56.59M | 63.38M | 97.05M | 139.99M | 150.34M | 319.1M |
| COGS % of Revenue | 116.68% | 0.02% | 0.05% | 0.11% | 0.15% | 0.12% | 0.14% | 0.15% | 0.12% | 0.17% |
| Gross Profit | -144.94M | 5.29M | 147.23M | 266.84M | 324.25M | 476.72M | 604.84M | 793.02M | 1.09B | 1.58B |
| Gross Margin % | -115.68% | 0.98% | 0.95% | 0.89% | 0.85% | 0.88% | 0.86% | 0.85% | 0.88% | 0.83% |
| Gross Profit Growth % | -0.72% | 1.04% | 26.83% | 0.81% | 0.22% | 0.47% | 0.27% | 0.31% | 0.38% | 0.45% |
| Operating Expenses | 221.44M | 272.02M | 290.44M | 610.47M | 1.03B | 1.04B | 1.06B | 1.33B | 1.36B | 1.36B |
| OpEx % of Revenue | 176.73% | 50.18% | 1.88% | 2.03% | 2.7% | 1.93% | 1.52% | 1.42% | 1.09% | 0.72% |
| Selling, General & Admin | 75.04M | 83.75M | 122.68M | 207.76M | 284.81M | 317.88M | 282.66M | 451.42M | 481.87M | 557.87M |
| SG&A % of Revenue | 59.89% | 15.45% | 0.79% | 0.69% | 0.75% | 0.59% | 0.4% | 0.48% | 0.39% | 0.29% |
| Research & Development | 146.39M | 188.27M | 166.71M | 401.84M | 560.91M | 722.34M | 771.18M | 877.09M | 877.39M | 804.52M |
| R&D % of Revenue | 116.83% | 34.73% | 1.08% | 1.33% | 1.47% | 1.34% | 1.1% | 0.94% | 0.71% | 0.42% |
| Other Operating Expenses | 0 | 0 | 1.98M | -656K | 184.09M | 662K | 10.71M | 714K | 1.56M | 2.4M |
| Operating Income | -220.18M | -266.73M | -171.64M | -343.63M | -705.56M | -564.16M | -459.71M | -536.2M | -267.82M | 218.08M |
| Operating Margin % | -175.73% | -49.2% | -1.11% | -1.14% | -1.85% | -1.04% | -0.65% | -0.57% | -0.22% | 0.11% |
| Operating Income Growth % | -0.65% | -0.21% | 0.36% | -1% | -1.05% | 0.2% | 0.19% | -0.17% | 0.5% | 1.81% |
| EBITDA | -214.94M | -261.12M | -163.55M | -331.38M | -681.06M | -524.42M | -421.69M | -481.6M | -208.93M | 271.97M |
| EBITDA Margin % | -171.54% | -48.17% | -1.06% | -1.1% | -1.79% | -0.97% | -0.6% | -0.52% | -0.17% | 0.14% |
| EBITDA Growth % | -0.65% | -0.21% | 0.37% | -1.03% | -1.06% | 0.23% | 0.2% | -0.14% | 0.57% | 2.3% |
| D&A (Non-Cash Add-back) | 5.25M | 5.61M | 8.09M | 12.24M | 24.5M | 39.74M | 38.02M | 54.6M | 58.89M | 53.89M |
| EBIT | -218.66M | -266.73M | -42.83M | -328.9M | -683.21M | -493.12M | -355.42M | -636.72M | -498.09M | 279.17M |
| Net Interest Income | -475K | -1.39M | -3.99M | -26.9M | -23.43M | -56.98M | -63.01M | -25.52M | 63.96M | 53.38M |
| Interest Income | 890K | 507K | 1.81M | 6.81M | 7.24M | 2.97M | 511K | 27.72M | 85.97M | 71.77M |
| Interest Expense | 1.36M | 1.89M | 5.78M | 33.71M | 30.67M | 59.95M | 63.52M | 53.25M | 22.01M | 18.39M |
| Other Income/Expense | 154K | -535K | 123.01M | -18.98M | -8.32M | 11.1M | 40.76M | -153.76M | -252.27M | 42.69M |
| Pretax Income | -220.03M | -267.26M | -48.63M | -362.61M | -713.88M | -553.07M | -418.95M | -689.96M | -520.1M | 260.77M |
| Pretax Margin % | -175.6% | -49.3% | -0.31% | -1.2% | -1.87% | -1.02% | -0.6% | -0.74% | -0.42% | 0.14% |
| Income Tax | 0 | 0 | 2.06M | -692K | 1.2M | 1.06M | -168K | 13.53M | 15.88M | 25.54M |
| Effective Tax Rate % | 1% | 1% | 1.04% | 1% | 1% | 1% | 1% | 1.02% | 1.03% | 0.9% |
| Net Income | -220.03M | -267.26M | -50.69M | -361.92M | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M | 235.24M |
| Net Margin % | -175.6% | -49.3% | -0.33% | -1.2% | -1.88% | -1.03% | -0.6% | -0.75% | -0.43% | 0.12% |
| Net Income Growth % | -0.62% | -0.21% | 0.81% | -6.14% | -0.98% | 0.23% | 0.24% | -0.68% | 0.24% | 1.44% |
| Net Income (Continuing) | -220.03M | -267.26M | -50.69M | -361.92M | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M | 235.24M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -5.20 | -5.49 | -0.86 | -5.46 | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 2.34 |
| EPS Growth % | -0.53% | -0.06% | 0.84% | -5.35% | -0.78% | 0.27% | 0.28% | -0.56% | 0.28% | 1.4% |
| EPS (Basic) | -5.20 | -5.49 | -0.86 | -5.46 | -9.71 | -7.11 | -5.15 | -8.03 | -5.80 | 2.47 |
| Diluted Shares Outstanding | 42.29M | 48.7M | 58.82M | 66.25M | 73.61M | 77.96M | 81.26M | 87.56M | 92.4M | 107.88M |
| Basic Shares Outstanding | 42.29M | 48.68M | 58.82M | 66.25M | 73.61M | 77.96M | 81.26M | 87.56M | 92.4M | 95.08M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 224.54M | 373.48M | 1.23B | 1.43B | 1.47B | 2.49B | 2.6B | 2.56B | 2.58B | 3.07B |
| Cash & Short-Term Investments | 192.49M | 317.85M | 1.08B | 1.17B | 1.12B | 1.94B | 2.12B | 1.99B | 1.68B | 1.35B |
| Cash Only | 80.3M | 122.42M | 599.69M | 370.83M | 835.08M | 1.5B | 2.12B | 966.78M | 428.43M | 1.1B |
| Short-Term Investments | 112.19M | 195.43M | 479.37M | 803.08M | 289.67M | 435.92M | 0 | 1.02B | 1.25B | 251.78M |
| Accounts Receivable | 3.98M | 5.23M | 29.47M | 49.04M | 93.94M | 138.58M | 172.75M | 261.6M | 436.98M | 649.73M |
| Days Sales Outstanding | 1.16K | 352.01 | 69.58 | 59.47 | 90.03 | 93.65 | 89.83 | 102.34 | 128.28 | 124.69 |
| Inventory | 26.87M | 12.81M | 83.61M | 125.44M | 171.38M | 231.96M | 186.21M | 203.97M | 322.86M | 749.96M |
| Days Inventory Outstanding | 67.1 | 35.97K | 4.15K | 1.34K | 1.11K | 1.34K | 700.34 | 531.82 | 783.83 | 857.84 |
| Other Current Assets | 24.97M | 35.21M | 22.41M | 62.14M | 59.52M | 138.5M | 5.3M | 6.82M | 12.48M | 9.21M |
| Total Non-Current Assets | 49.24M | 50.63M | 79.32M | 215.89M | 353.91M | 499.52M | 543.88M | 570.5M | 685.25M | 889.71M |
| Property, Plant & Equipment | 37.34M | 37.8M | 43.16M | 97.02M | 167.55M | 282.19M | 236.69M | 244.99M | 357.11M | 488.65M |
| Fixed Asset Turnover | 0.03x | 0.14x | 3.58x | 3.10x | 2.27x | 1.91x | 2.97x | 3.81x | 3.48x | 3.89x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 6.64M | 8.08M | 14.36M | 11.57M | 12.5M | 13.63M | 14.24M | 7.58M | 29.62M | 26.89M |
| Long-Term Investments | 783K | 0 | 9.98M | 107.29M | 41.5M | 48.11M | 34.89M | 31.32M | 6.53M | 136.87M |
| Other Non-Current Assets | 5.25M | 4.75M | 21.81M | 107.29M | 132.36M | 155.59M | 258.06M | 286.62M | 291.99M | 237.3M |
| Total Assets | 273.78M | 424.1M | 1.31B | 1.64B | 1.82B | 2.98B | 3.15B | 3.13B | 3.26B | 3.96B |
| Asset Turnover | 0.00x | 0.01x | 0.12x | 0.18x | 0.21x | 0.18x | 0.22x | 0.30x | 0.38x | 0.48x |
| Asset Growth % | -0.07% | 0.55% | 2.08% | 0.26% | 0.11% | 0.64% | 0.05% | -0.01% | 0.04% | 0.21% |
| Total Current Liabilities | 62.29M | 75.42M | 88.33M | 173.69M | 264.77M | 416.03M | 452.73M | 619.6M | 653.66M | 731.68M |
| Accounts Payable | 20.23M | 29.69M | 8.47M | 33.83M | 68.09M | 111.09M | 76.74M | 95.88M | 164.92M | 214.44M |
| Days Payables Outstanding | 50.52 | 83.36K | 420.3 | 361.11 | 439.23 | 639.74 | 288.62 | 249.98 | 400.38 | 245.29 |
| Short-Term Debt | 8.43M | 10.11M | 6.17M | 0 | 7.85M | 20.93M | 0 | 0 | 105.48M | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 1000K | 1000K | 0 | 1000K | 1000K | 1000K | 1000K | 1000K |
| Other Current Liabilities | 22.14M | 23.57M | 55.03M | 111.56M | 145.59M | 143.96M | 110.44M | 134.73M | 178.81M | 200.28M |
| Current Ratio | 3.60x | 4.95x | 13.91x | 8.21x | 5.55x | 5.97x | 5.75x | 4.13x | 3.95x | 4.20x |
| Quick Ratio | 3.17x | 4.78x | 12.96x | 7.49x | 4.90x | 5.42x | 5.34x | 3.80x | 3.45x | 3.18x |
| Cash Conversion Cycle | 1.18K | -47.03K | 3.8K | 1.04K | 756.26 | 789.72 | 501.55 | 384.18 | 511.73 | 737.24 |
| Total Non-Current Liabilities | 21.14M | 11.99M | 430.42M | 436.11M | 739.87M | 1.81B | 1.77B | 2.12B | 1.75B | 1.7B |
| Long-Term Debt | 14.97M | 6.04M | 424.88M | 420.55M | 681.9M | 992.49M | 1.1B | 1.54B | 1.13B | 1.14B |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 47.72M | 80.37M | 41.51M | 57.58M | 140.97M | 192.47M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 6.17M | 5.95M | 5.54M | 15.55M | 10.25M | 70.58M | 54.6M | 36.94M | 41.1M | 49.15M |
| Total Liabilities | 83.44M | 87.41M | 518.75M | 609.8M | 1B | 2.22B | 2.22B | 2.74B | 2.41B | 2.44B |
| Total Debt | 23.4M | 16.15M | 431.05M | 420.55M | 737.47M | 1.09B | 1.15B | 1.62B | 1.4B | 1.34B |
| Net Debt | -56.91M | -106.27M | -168.64M | 49.73M | -97.61M | -408.86M | -962.43M | 650.58M | 968.38M | 240.06M |
| Debt / Equity | 0.12x | 0.05x | 0.55x | 0.41x | 0.90x | 1.44x | 1.24x | 4.20x | 1.63x | 0.88x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | 4.94x |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 0.88x |
| Interest Coverage | -161.31x | -140.98x | -29.69x | -10.19x | -23.01x | -9.41x | -7.24x | -10.07x | -12.17x | 11.86x |
| Total Equity | 190.35M | 336.69M | 789.22M | 1.03B | 818.19M | 761.76M | 928.01M | 384.95M | 859.34M | 1.53B |
| Equity Growth % | -0.23% | 0.77% | 1.34% | 0.31% | -0.21% | -0.07% | 0.22% | -0.59% | 1.23% | 0.78% |
| Book Value per Share | 4.50 | 6.91 | 13.42 | 15.58 | 11.11 | 9.77 | 11.42 | 4.40 | 9.30 | 14.16 |
| Total Shareholders' Equity | 190.35M | 336.69M | 789.22M | 1.03B | 818.19M | 761.76M | 928.01M | 384.95M | 859.34M | 1.53B |
| Common Stock | 5K | 5K | 6K | 7K | 8K | 8K | 9K | 9K | 9K | 10K |
| Retained Earnings | -899.05M | -1.17B | -1.22B | -1.58B | -2.29B | -2.85B | -3.21B | -3.91B | -4.45B | -4.21B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -111K | -120K | -379K | -99K | 50K | 3K | -20K | -1.66M | 918K | -218K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -149.47M | -245.82M | -232M | -388.66M | -456.46M | 107.47M | -443.17M | -325.35M | -500.99M | -205.79M |
| Operating CF Margin % | -119.29% | -45.35% | -1.5% | -1.29% | -1.2% | 0.2% | -0.63% | -0.35% | -0.4% | -0.11% |
| Operating CF Growth % | -0.16% | -0.64% | 0.06% | -0.68% | -0.17% | 1.24% | -5.12% | 0.27% | -0.54% | 0.59% |
| Net Income | -220.03M | -267.26M | -50.69M | -361.92M | -715.08M | -554.13M | -418.78M | -703.49M | -535.98M | 235.24M |
| Depreciation & Amortization | 5.25M | 5.61M | 8.09M | 12.24M | 24.5M | 26.91M | 38.02M | 41.86M | 44.4M | 37.72M |
| Stock-Based Compensation | 32.12M | 29.96M | 30.46M | 50.13M | 78.6M | 108.07M | 113.94M | 233.02M | 182.51M | 184.3M |
| Deferred Taxes | 849K | 373K | -83K | -1.41M | 0 | 10.64M | 15.81M | 0 | 0 | 0 |
| Other Non-Cash Items | 367K | 1.27M | -122.32M | 20.19M | 222.39M | -38.09M | -94M | 142.73M | 289.16M | 53.56M |
| Working Capital Changes | 31.98M | -15.77M | -97.46M | -107.89M | -66.88M | 554.06M | -98.17M | -39.47M | -481.09M | -716.61M |
| Change in Receivables | -1.56M | -1.25M | -24.24M | -19.58M | -41.84M | -10.46M | -51.65M | -61.64M | -185.7M | -201.66M |
| Change in Inventory | -147M | -12.81M | -70.79M | -41.84M | -45.93M | -60.58M | -83.77M | -50.78M | -147.71M | -395.17M |
| Change in Payables | 18.3M | 7.31M | 12.93M | 90.16M | 122.98M | 42M | 23.3M | 147.57M | -50.13M | 110.65M |
| Cash from Investing | 8.41M | -90.19M | -178.81M | -370.49M | 286.73M | -121.72M | 495.41M | -1.05B | -165.8M | 755.56M |
| Capital Expenditures | -4.83M | -6.87M | -21.21M | -64.34M | -59.63M | -82.2M | -38.49M | -30.82M | -76.11M | -136.96M |
| CapEx % of Revenue | 3.86% | 1.27% | 0.14% | 0.21% | 0.16% | 0.15% | 0.05% | 0.03% | 0.06% | 0.07% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -1.43M | -1.52M | 134.22M | -3.19M | -3.08M | 104.57M | 97.89M | -1.43M | 90.76M | -10M |
| Cash from Financing | 147.81M | 378.13M | 888.08M | 530.15M | 642.55M | 682.32M | 561.57M | 232.51M | 125M | 124.81M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 10.49M | 20.93M | -50.83M | 563.63M | 31.57M | 79.12M | 13.04M | -71.66M | 125M | 45.35M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -154.3M | -252.69M | -253.21M | -453M | -516.09M | 25.26M | -481.66M | -357.6M | -588.34M | -342.74M |
| FCF Margin % | -123.14% | -46.61% | -1.64% | -1.5% | -1.36% | 0.05% | -0.69% | -0.38% | -0.47% | -0.18% |
| FCF Growth % | 0.01% | -0.64% | -0% | -0.79% | -0.14% | 1.05% | -20.07% | 0.26% | -0.65% | 0.42% |
| FCF per Share | -3.65 | -5.19 | -4.30 | -6.84 | -7.01 | 0.32 | -5.93 | -4.08 | -6.37 | -3.18 |
| FCF Conversion (FCF/Net Income) | 0.68x | 0.92x | 4.58x | 1.07x | 0.64x | -0.19x | 1.06x | 0.46x | 0.93x | -0.87x |
| Interest Paid | 0 | 0 | 1.91M | 11.31M | 8.55M | 34.42M | 55.95M | 44.42M | 15.92M | 15.86M |
| Taxes Paid | 0 | 0 | 5.34M | 1.55M | 933K | 2.51M | 583K | 1.7M | 15.08M | 22.59M |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -100.47% | -101.42% | -9% | -39.74% | -77.29% | -70.15% | -49.57% | -107.16% | -86.15% | 19.71% |
| Return on Invested Capital (ROIC) | -105.23% | -109.96% | -30.25% | -30.27% | -58.71% | -78.83% | -216.52% | -80.34% | -14.03% | 9.1% |
| Gross Margin | -11567.52% | 97.6% | 95.24% | 88.64% | 85.14% | 88.26% | 86.17% | 85% | 87.91% | 83.22% |
| Net Margin | -17560.26% | -4930.18% | -32.79% | -120.23% | -187.77% | -102.6% | -59.66% | -75.4% | -43.11% | 12.37% |
| Debt / Equity | 0.12x | 0.05x | 0.55x | 0.41x | 0.90x | 1.44x | 1.24x | 4.20x | 1.63x | 0.88x |
| Interest Coverage | -161.31x | -140.98x | -29.69x | -10.19x | -23.01x | -9.41x | -7.24x | -10.07x | -12.17x | 11.86x |
| FCF Conversion | 0.68x | 0.92x | 4.58x | 1.07x | 0.64x | -0.19x | 1.06x | 0.46x | 0.93x | -0.87x |
| Revenue Growth | -87.16% | 332.64% | 2751.58% | 94.74% | 26.51% | 41.82% | 29.96% | 32.93% | 33.26% | 52.97% |
| 2022 | 2023 | 2024 | |
|---|---|---|---|
| UNITED STATES | 747.1M | 797.94M | 820.79M |
| UNITED STATES Growth | - | 6.81% | 2.86% |
| World | - | 146.58M | 150.25M |
| World Growth | - | - | 2.51% |
| Non-US | 96.7M | - | - |
| Non-US Growth | - | - | - |
Sarepta Therapeutics, Inc. (SRPT) has a price-to-earnings (P/E) ratio of 9.1x. This may indicate the stock is undervalued or faces growth challenges.
Sarepta Therapeutics, Inc. (SRPT) reported $2.41B in revenue for fiscal year 2024. This represents a 5037% increase from $47.0M in 2011.
Sarepta Therapeutics, Inc. (SRPT) grew revenue by 53.0% over the past year. This is strong growth.
Sarepta Therapeutics, Inc. (SRPT) reported a net loss of $271.5M for fiscal year 2024.
Sarepta Therapeutics, Inc. (SRPT) has a return on equity (ROE) of 19.7%. This is reasonable for most industries.
Sarepta Therapeutics, Inc. (SRPT) had negative free cash flow of $343.6M in fiscal year 2024, likely due to heavy capital investments.